QVOKLY
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

QVOKLY Trademark

Serial Number: 90008232 • Registration: 7575037

QVOKLY is a trademark filed by Ascendis Pharma Endocrinology Division A/S on June 18, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Ascendis Pharma Endocrinology Division A/S (14 trademarks)

Hellerup 2900 , DK

Entity Type: 99

Trademark Details

Filing Date

June 18, 2020

Registration Date

November 26, 2024

Published for Opposition

September 21, 2021

Goods & Services

Downloadable computer software and downloadable computer programs for use in providing medical advice and advice on medications for treatment, patient assistance and health insurance in the field of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for sharing information related to growth disorders, endocrine disorders, bone disorders, cancer, infectious diseases and the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases for use by patients with growth hormone disorders, hypoparathyroidism, skeletal dysplasia, and diabetes in the medical field of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; downloadable computer application software for mobile phones, tablet computers handheld computers and personal computers, namely, downloadable software that coordinates the delivery of health care services between health care providers, patients and those parties responsible for the payment of health care services, namely, downloadable software that allows individuals seeking medical education, information and services to locate a physician and treatment facility in their geographic area for medical treatment and allows physicians and health care professionals to communicate their credentials and specialization to patients and parties responsible for payment of healthcare services; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, downloadable software that enables health care providers to monitor patients, communicate clinical information relevant to a patient's care, provide and exchange information concerning patients and the health care services provided to patients; downloadable software, downloadable software applications and downloadable mobile applications for providing co-pay and other financial or medical access support; downloadable computer software for providing a communications platform enabling users to share health and healthcare information; downloadable software, downloadable software applications and downloadable mobile applications for the measurement of height, weight, blood pressure, serum calcium, blood glucose, and heart rate; downloadable software, downloadable software applications and downloadable mobile applications for providing, exchanging, retrieving and analyzing health and healthcare information; downloadable software for medical purposes, namely, for formatting, viewing and transmitting medical data collected and stored on hormone injection pens and pumps and between said injection pens and pumps and portable electronic devices; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for providing healthcare-related information, medication reminders, and tracking medication dosing history; the foregoing downloadable software related to pharmaceutical preparations for the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases

Pharmaceutical preparations for the treatment of growth disorders, pharmaceutical preparations for the treatment of endocrine disorders, pharmaceutical preparations for the treatment of bone disorders, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations for the treatment of infectious diseases; diagnostic preparations for medical purposes, namely, diagnostic preparations for identifying and detecting growth hormone deficiency, endocrine disorders, bone disorders, cancer, and infectious diseases

Medical devices for injection, dosage and control of pharmaceuticals, namely, medical devices for injection, dosage measurement and monitoring of pharmaceuticals for the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; syringes for medical purposes and for injections; syringes for injection for medical and surgical use, namely, syringes in the form of pens for surgical use; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with management of growth hormone disorders, hypoparathyroidism, skeletal dysplasia, cancer and diabetes; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus for diagnostic purposes, namely, medicine dosage dispensers containing software featuring web-based medical information for physical and psychological examination and assessment of patients remotely and at a clinic; dosage management dispensers containing software for medical information management for guidance and control of medicines and for therapeutic use in web-based physical and psychological examination and assessment of patients remotely and at a clinic

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 26, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 26, 2024 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Nov 4, 2024 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 30, 2024 AITU
NOTICE OF ALLOWANCE CANCELLED
May 16, 2024 IUCN
TEAS POST PUBLICATION AMENDMENT RECEIVED
May 16, 2024 EPPA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 18, 2023 EXRA
SOU EXTENSION 4 GRANTED
Nov 16, 2023 EX4G
SOU EXTENSION 4 FILED
Nov 16, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 16, 2023 EEXT
ASSIGNED TO EXAMINER
Nov 13, 2023 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 16, 2023 EXRA
SOU EXTENSION 3 GRANTED
May 12, 2023 EX3G
SOU EXTENSION 3 FILED
May 12, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
May 12, 2023 EEXT
ASSIGNED TO EXAMINER
May 2, 2023 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 18, 2022 EXRA
SOU EXTENSION 2 GRANTED
Nov 16, 2022 EX2G
SOU EXTENSION 2 FILED
Nov 16, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 16, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 14, 2022 EXRA
SOU EXTENSION 1 GRANTED
May 12, 2022 EX1G
SOU EXTENSION 1 FILED
May 12, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
May 12, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 16, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 21, 2021 NPUB
PUBLISHED FOR OPPOSITION
Sep 21, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 1, 2021 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Aug 17, 2021 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Aug 13, 2021 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 12, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 13, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 13, 2021 CRFA
ASSIGNED TO LIE
Jul 9, 2021 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 26, 2021 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 22, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 22, 2021 GNSL
SUSPENSION LETTER WRITTEN
Apr 22, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 22, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 22, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 22, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 22, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 22, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 22, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 22, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 16, 2020 NWOS
NEW APPLICATION ENTERED
Jun 22, 2020 NWAP